Quince Therapeutics Inc (QNCX): Next-Year EPS Estimate 69.23%
As of 2026-05-11, Quince Therapeutics Inc (QNCX) has a next-year EPS growth estimate of 69.23%.
On 2026-05-10, analyst consensus for QNCX's next-year EPS growth shifted from 91.73% to 69.23% — a negative change of 22.50 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at 74.26%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 69.23%
- EPS growth this year
- 74.26%
- EPS next quarter (est)
- -$1.30
- Last price
- $1.24
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-11 | 69.23% | 74.26% | -$1.30 | $1.24 |
| 2026-05-10 | 69.23% | 74.26% | -$1.30 | $1.28 |
| 2026-05-07 | 91.73% | 39.41% | -$1.41 | $1.30 |
| 2026-05-06 | 92.11% | 38.99% | -$1.56 | $1.22 |
| 2026-05-05 | 92.11% | 38.99% | -$1.56 | $1.23 |
| 2026-05-04 | 92.11% | 38.99% | -$1.56 | $1.22 |
| 2026-05-03 | 92.11% | 38.99% | -$1.56 | $1.33 |
| 2026-04-30 | 92.11% | 38.99% | -$1.56 | $1.31 |
| 2026-04-29 | 92.11% | 38.99% | -$1.56 | $1.23 |
| 2026-04-28 | 92.11% | 38.99% | -$1.56 | $1.23 |
| 2026-04-27 | 92.11% | 38.99% | -$1.56 | $1.29 |
| 2026-04-26 | 92.11% | 38.99% | -$1.56 | $1.36 |
| 2026-04-24 | 92.11% | 38.99% | -$1.56 | $1.36 |
| 2026-04-23 | 92.11% | 38.99% | -$1.56 | $1.36 |
| 2026-04-22 | 92.11% | 38.99% | -$1.56 | $1.37 |
| 2026-04-21 | 92.11% | 38.99% | -$1.56 | $1.34 |
| 2026-04-20 | 92.11% | 38.99% | -$1.56 | $1.27 |
| 2026-04-19 | 92.11% | 38.99% | -$1.56 | $1.37 |
| 2026-04-16 | 92.11% | 38.99% | -$1.56 | $1.34 |
| 2026-04-15 | 92.11% | 38.99% | -$1.56 | $1.23 |
| 2026-04-14 | 92.11% | 38.99% | -$1.56 | $1.25 |
| 2026-04-13 | 92.11% | 38.99% | -$1.56 | $1.41 |
| 2026-04-12 | 92.11% | 38.99% | -$0.16 | $0.14 |
| 2026-04-10 | 92.11% | 38.99% | -$0.16 | $0.14 |
| 2026-04-09 | 92.11% | 38.99% | -$0.16 | $0.12 |
| 2026-04-08 | 92.11% | N/A | -$0.16 | $0.18 |
| 2026-04-07 | 92.11% | N/A | -$0.16 | $0.16 |
| 2026-04-06 | 92.11% | N/A | -$0.16 | $0.16 |
| 2026-04-05 | 92.11% | N/A | -$0.16 | $0.10 |
| 2026-04-03 | 92.11% | N/A | -$0.16 | $0.16 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Quince Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-05-11, Quince Therapeutics Inc (QNCX) has a next-year EPS growth estimate of 69.23%, based on analyst consensus.
When was the latest EPS estimate revision for QNCX?▾
The most recent revision occurred on 2026-05-10, when analysts adjusted the next-year EPS growth estimate from 91.73% to 69.23%.
What sector and industry does Quince Therapeutics Inc belong to?▾
Quince Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. QNCX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Quince Therapeutics Inc (QNCX) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports